Comera Life Sciences Holdings, Inc. Common Stock
CMRA
CMRA was delisted on the 16th of November, 2023.
11 hedge funds and large institutions have $190K invested in Comera Life Sciences Holdings, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 0 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
8% less funds holding
Funds holding: 12 → 11 (-1)
70% less capital invested
Capital invested by funds: $643K → $190K (-$453K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.37K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.04K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$126 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$30 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.26K |
| 2 |
Morgan Stanley
New York
|
-$4 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Geode Capital Management
Boston,
Massachusetts
| $53.9K | – | – | – |
|
2
HighTower Advisors
Chicago,
Illinois
| $43K | – | – | – |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $39.6K | +$126 | +100 | +0.2% |
|
4
State Street
Boston,
Massachusetts
| $26.6K | – | – | – |
|
|
5
Osaic Holdings
Scottsdale,
Arizona
| $17K | -$1.26K | -1,000 | -5% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $5K | +$5.37K | +4,272 | +330% |
|
|
7
Morgan Stanley
New York
| $2.06K | -$4 | -3 | -0.1% |
|
|
8
UBS Group
Zurich,
Switzerland
| $1.85K | +$1.04K | +826 | +67% |
|
|
WAM
9
Wolverine Asset Management
Chicago,
Illinois
| $586 | – | – | – |
|
|
10
Wells Fargo
San Francisco,
California
| $68 | +$30 | +24 | +46% |
|
CMRA Hedge Fund Activity: Q1 2023 in Review
11 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Comera Life Sciences Holdings, Inc. Common Stock (CMRA) for Q1 2023, worth a combined $190K — down 70% from $643K a quarter earlier.
Fund positioning in CMRA was balanced in Q1 2023: 0 funds opened new positions, 0 closed out, 4 added to existing stakes and 2 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $5.37K. The largest seller was Osaic Holdings, cutting an estimated $1.26K.
- 11 institutional investors held Comera Life Sciences Holdings, Inc. Common Stock (CMRA) as of Q1 2023, down from 12 in Q4 2022.
- Funds reported $190K of Comera Life Sciences Holdings, Inc. Common Stock stock for Q1 2023, down 70% quarter-over-quarter.
- 0 funds opened new Comera Life Sciences Holdings, Inc. Common Stock positions in Q1 2023 and 0 closed out.
- The largest Comera Life Sciences Holdings, Inc. Common Stock buyer in Q1 2023 was Tower Research Capital (TRC), an estimated $5.37K added.
- The largest Comera Life Sciences Holdings, Inc. Common Stock seller in Q1 2023 was Osaic Holdings, an estimated $1.26K sold.
Based on aggregated 13F filings for Q1 2023.